Revolution Medicines (RVMD) is back in focus after Rasonque received US approval and a positive opinion from Europe’s medicines regulator for adults with metastatic pancreatic adenocarcinoma, which is sharpening attention on the company’s RAS-focused pipeline.
The latest excitement around Rasonque is landing after a choppy spell for Revolution Medicines’ stock, with the share price down 6.4% over one day and 9.5% over the past week, yet still showing a strong year to date share price return of 128.7% and a very large three year total shareholder return that reflects how sentiment has shifted over a longer horizon.
See how Revolution Medicines compares with other high potential biotech names screened for resilience and upside in our curated list of 19 high quality undiscovered gems.
Revolution Medicines now pairs a freshly approved RAS drug with a long record of heavy losses and a share price that has surged this year. Given that mix, is the current valuation still sensible?
Most Popular Narrative: 30.9% Undervalued
At a last close of $180.70, Revolution Medicines sits well below the analyst consensus Narrative fair value of $261.47, which the analyst consensus Narrative on Simply Wall St builds from detailed revenue, earnings and risk assumptions rather than a single price target headline.
The move toward targeted oncology treatments for high unmet need tumors such as pancreatic, lung and colorectal cancer aligns with the company’s RAS(ON) portfolio, which could influence long term revenue growth if multiple registrational programs convert to approved therapies.
Eight ongoing or planned Phase III registrational trials and clinical experience in more than 2,500 patients create multiple data points over the next few years that could change how investors view the durability and scale of the pipeline, with potential implications for future revenue visibility and earnings power.
See why 19 investors see Revolution Medicines as 31% undervalued.
Result: Fair Value of $261.47 (UNDERVALUED)
Still, the Revolution Medicines story could shift quickly if its concentrated RAS oncology bets face trial setbacks, or if heavy 2026 operating expenses drag on sentiment.
Find out about the key risks to this Revolution Medicines narrative.
Another View: Valuing Revolution Medicines Through P/B
The analyst fair value narrative presents Revolution Medicines as 30.9% undervalued, yet the share price already reflects a rich balance sheet multiple. RVMD trades on a P/B of 16.3x compared with 1.9x for the wider US Biotechs group and 17.9x for closer peers. This suggests investors are already paying a steep premium for its assets. If sentiment cools and the ratio moves toward the broader industry or peer levels instead of increasing further, how comfortable are you with that valuation gap?
See what the numbers indicate about this price in our valuation breakdown, then compare that against your own expectations for the business See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Sentiment around Revolution Medicines is clearly divided, which is exactly why it pays to move quickly, review the numbers yourself and stress test both the upside and the risks. To weigh those trade offs in one place, start with the 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Revolution Medicines?
If Revolution Medicines has your attention, do not stop here. Fresh opportunities often emerge where the crowd is not looking yet.
- Spot potential bargains early and compare them with Revolution Medicines by scanning our curated 32 high quality undervalued stocks tailored to strong fundamentals and appealing pricing.
- Prioritize resilience over drama by checking a 30 resilient stocks with low risk scores that highlights businesses with sturdier risk profiles than many headline stocks.
- Strengthen your watchlist with a list of solid balance sheet and fundamentals (23 results) that focuses on companies backed by healthier finances and cleaner balance sheets.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com